Cargando…
Durable biochemical response following adrenal metastasectomy for oligometastatic castrate-resistant prostate cancer
A 77 year-old man was referred to Urology with an enlarging left adrenal mass after treatment with androgen deprivation therapy for metastatic castrate-resistant prostate cancer. He underwent a robotic-assisted left radical adrenalectomy, with pathology revealing metastatic adenocarcinoma consistent...
Autores principales: | Ashrafi, Akbar N., Fay, Carlos, Yip, Wesley, de Freitas, Daniel M., Nabhani, Jamal, Aron, Monish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217987/ https://www.ncbi.nlm.nih.gov/pubmed/32420037 http://dx.doi.org/10.1016/j.eucr.2020.101229 |
Ejemplares similares
-
Neoadjuvant Therapy in High-Risk Prostate Cancer
por: Ashrafi, Akbar N., et al.
Publicado: (2020) -
Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
por: Katano, Atsuto, et al.
Publicado: (2021) -
Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021) -
Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer
por: Kroese, Tiuri E., et al.
Publicado: (2022) -
Metastasectomy of oligometastatic urothelial cancer: a single-center experience
por: Muilwijk, Tim, et al.
Publicado: (2020)